BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22301195)

  • 1. Citalopram for agitation in Alzheimer's disease: design and methods.
    Drye LT; Ismail Z; Porsteinsson AP; Rosenberg PB; Weintraub D; Marano C; Pelton G; Frangakis C; Rabins PV; Munro CA; Meinert CL; Devanand DP; Yesavage J; Mintzer JE; Schneider LS; Pollock BG; Lyketsos CG;
    Alzheimers Dement; 2012; 8(2):121-30. PubMed ID: 22301195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
    Porsteinsson AP; Drye LT; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
    JAMA; 2014 Feb; 311(7):682-91. PubMed ID: 24549548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
    Ehrhardt S; Porsteinsson AP; Munro CA; Rosenberg PB; Pollock BG; Devanand DP; Mintzer J; Rajji TK; Ismail Z; Schneider LS; Baksh SN; Drye LT; Avramopoulos D; Shade DM; Lyketsos CG;
    Alzheimers Dement; 2019 Nov; 15(11):1427-1436. PubMed ID: 31587995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
    Peters ME; Vaidya V; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Avramopoulos D;
    J Geriatr Psychiatry Neurol; 2016 Mar; 29(2):59-64. PubMed ID: 26303700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.
    Newell J; Yesavage JA; Taylor JL; Kraemer HC; Munro CA; Friedman L; Rosenberg PB; Madore M; Chao SZ; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
    J Psychiatr Res; 2016 Mar; 74():17-21. PubMed ID: 26736036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.
    Weintraub D; Drye LT; Porsteinsson AP; Rosenberg PB; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Yesavage J; Lyketsos CG;
    Am J Geriatr Psychiatry; 2015 Nov; 23(11):1127-33. PubMed ID: 26238225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
    Rosenberg PB; Drye LT; Porsteinsson AP; Pollock BG; Devanand DP; Frangakis C; Ismail Z; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Rabins PV; Schneider LS; Shade DM; Weintraub D; Newell J; Yesavage J; Lyketsos CG;
    Int Psychogeriatr; 2015 Dec; 27(12):2059-67. PubMed ID: 26305876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of citalopram in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Keltz MA; Smith JS
    Neurodegener Dis Manag; 2014; 4(5):345-9. PubMed ID: 25405648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
    Schneider LS; Frangakis C; Drye LT; Devanand DP; Marano CM; Mintzer J; Mulsant BH; Munro CA; Newell JA; Pawluczyk S; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rein L; Rosenberg PB; Shade D; Weintraub D; Yesavage J; Lyketsos CG;
    Am J Psychiatry; 2016 May; 173(5):465-72. PubMed ID: 26771737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressants for agitation and psychosis in dementia.
    Seitz DP; Adunuri N; Gill SS; Gruneir A; Herrmann N; Rochon P
    Cochrane Database Syst Rev; 2011 Feb; (2):CD008191. PubMed ID: 21328305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
    Drye LT; Spragg D; Devanand DP; Frangakis C; Marano C; Meinert CL; Mintzer JE; Munro CA; Pelton G; Pollock BG; Porsteinsson AP; Rabins PV; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG;
    PLoS One; 2014; 9(6):e98426. PubMed ID: 24914549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Principal components analysis of agitation outcomes in Alzheimer's disease.
    Yesavage JA; Taylor JL; Friedman L; Rosenberg PB; Lazzeroni LC; Leoutsakos JS; Kinoshita LM; Perlow MJ; Munro CA; Devanand DP; Drye LT; Mintzer JE; Pollock BG; Porsteinsson AP; Schneider LS; Shade DM; Weintraub D; Lyketsos CG; Noda A;
    J Psychiatr Res; 2016 Aug; 79():4-7. PubMed ID: 27115509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.
    Tao Y; Peters ME; Drye LT; Devanand DP; Mintzer JE; Pollock BG; Porsteinsson AP; Rosenberg PB; Schneider LS; Shade DM; Weintraub D; Yesavage J; Lyketsos CG; Munro CA
    Am J Alzheimers Dis Other Demen; 2018 Nov; 33(7):450-457. PubMed ID: 29969907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.
    Ho T; Pollock BG; Mulsant BH; Schantz O; Devanand DP; Mintzer JE; Porsteinsson AP; Schneider LS; Weintraub D; Yesavage J; Drye LT; Munro CA; Shade DM; Lyketsos C; Bies R
    Br J Clin Pharmacol; 2016 Sep; 82(3):784-92. PubMed ID: 27145364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects.
    Underwood BR; Fox C
    Evid Based Med; 2014 Oct; 19(5):181. PubMed ID: 24824622
    [No Abstract]   [Full Text] [Related]  

  • 16. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia.
    Pollock BG; Mulsant BH; Rosen J; Mazumdar S; Blakesley RE; Houck PR; Huber KA
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):942-52. PubMed ID: 17846102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram.
    Aga VM
    Am J Geriatr Psychiatry; 2019 Oct; 27(10):1099-1107. PubMed ID: 31288974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating dementia and agitation.
    Small GW
    JAMA; 2014 Feb; 311(7):677-8. PubMed ID: 24549545
    [No Abstract]   [Full Text] [Related]  

  • 19. A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease.
    Scharre DW; Davis RA; Warner JL; Chang SI; Beversdorf DQ
    Am J Geriatr Psychiatry; 2003; 11(6):687-91. PubMed ID: 14609811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease.
    Choe YM; Kim KW; Jhoo JH; Ryu SH; Seo EH; Sohn BK; Byun MS; Bak JH; Lee JM; Yun HJ; Han MI; Woo JI; Lee DY
    Int J Geriatr Psychiatry; 2016 Jul; 31(7):731-9. PubMed ID: 26553313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.